Overview
Zynex Q2 2025 revenue falls 55% yr/yr, missing analyst expectations, per LSEG data
Net loss widens to $20 mln, or $0.66 per share, in Q2 2025
Co appoints Steven Dyson as new CEO, aims for strategic refocus
Outlook
Company suspends revenue and profitability guidance due to leadership changes
New CEO to review forecasting procedures and update investors
Company expects $40 mln annualized savings to take effect in Q3 and Q4
Result Drivers
REVENUE DECLINE - Revenue impacted by Tricare payment suspension and changes to shipment and billing procedures
FDA SUBMISSION - NiCO laser pulse oximeter submitted to FDA, marking a milestone in product development
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $22.30 mln | $27.40 mln (3 Analysts) |
Q2 EPS | -$0.66 | ||
Q2 Net Income | -$20 mln | ||
Q2 Adjusted EBITDA | -$8.90 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Zynex Inc is $6.00, about 58.5% above its July 30 closing price of $2.49
Press Release: ID:nPn5CVS51a
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)